Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination Therapy With Liposomal Doxorubicin and Withaferin A (Ashwagandha, ASWD) in Recurrent Ovarian Cancer

NCT05610735 is registered in ClinicalTrials.gov with Sham Sunder Kakar as lead sponsor.

NCT NCT05610735
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05610735 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination Therapy With Liposomal Doxorubicin and Withaferin A (Ashwagandha, ASWD) in Recurrent Ovarian Cancer
Lead sponsor
Sham Sunder Kakar
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 25, 2024
Completion date
November 30, 2028
Enrollment
72 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent ovarian cancer